Age-Related Maculopathy

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
RN6GPhase 11 trial
Active Trials
NCT00877032CompletedEst. Jul 2011
Genentech
GenentechCA - Oceanside
1 program
LucentisN/A1 trial
Active Trials
NCT00474695Terminated65Est. Dec 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerRN6G
GenentechLucentis

Clinical Trials (2)

Total enrollment: 65 patients across 2 trials

Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration

Start: Apr 2009Est. completion: Jul 2011
Phase 1Completed

Study Evaluating Genotypes Using Lucentis

Start: May 2007Est. completion: Dec 200965 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space